What is CoLucid Pharmaceuticals' stock symbol?
CoLucid Pharmaceuticals trades on the NASDAQ under the ticker symbol "CLCD."
Where is CoLucid Pharmaceuticals' stock going? Where will CoLucid Pharmaceuticals' stock price be in 2017?
6 analysts have issued 12-month target prices for CoLucid Pharmaceuticals' shares. Their predictions range from $40.00 to $57.00. On average, they expect CoLucid Pharmaceuticals' share price to reach $48.10 in the next year.
When will CoLucid Pharmaceuticals announce their earnings?
CoLucid Pharmaceuticals is scheduled to release their next quarterly earnings announcement on Wednesday, November, 9th 2016.
What are analysts saying about CoLucid Pharmaceuticals stock?
Here are some recent quotes from research analysts about CoLucid Pharmaceuticals stock:
- Piper Jaffray Companies analysts commented, "We see this announcement as resulting from CoLucid's clean design and execution of its Phase III program for oral lasmiditan, and expect the second Phase III SPARTAN trial to read out on schedule in 3Q17. On the GLADIATOR open-label study, we believe that retention rates remain at >70% and that Lilly has likely performed thorough diligence on ongoing safety, efficacy, and compliance in the program. Therefore we see relatively low risk to new information arising in the near-term which threatens completion of this transaction. Overall, the bid confirms our long-held thesis around clinical value of a new acute migraine treatment that provides advantages over standard-of-care triptans on CV safety as well as efficacy for some patients. At this time, we are reducing our rating for CLCD to Neutral." (1/18/2017)
According to Zacks Investment Research, "CoLucid Pharmaceuticals, Inc. is a biopharmaceutical company which develops molecule for the treatment of migraine headaches. The company's product candidate consists of oral Lasmiditan for the treatment of migraine headache and intravenous lasmiditan for treatment of headache pain, which are in different clinical trial. CoLucid Pharmaceuticals, Inc. is headquartered in Burlington, Massachusetts. " (1/10/2017)
Who owns CoLucid Pharmaceuticals stock?
CoLucid Pharmaceuticals' stock is owned by many different of institutional and retail investors. Top institutional shareholders include Novo A S (16.40%), FMR LLC (6.85%), Perceptive Advisors LLC (3.33%), Marshall Wace LLP (2.52%), Vivo Capital LLC (1.17%) and J. Goldman & Co LP (0.67%). Company insiders that own CoLucid Pharmaceuticals stock include A/S Novo, Arthur M Pappas, Bernice Kuca, Domain Partners Vi, LP, Linda C Hogan, Matthew D Dallas, Raymond Skwierczynski, Thomas P Mathers and Vi Associates LP Dp.
Who sold CoLucid Pharmaceuticals stock? Who is selling CoLucid Pharmaceuticals stock?
CoLucid Pharmaceuticals' stock was sold by a variety of institutional investors in the last quarter, including Kingdon Capital Management L.L.C., Renaissance Technologies LLC and Artal Group S.A.. Company insiders that have sold CoLucid Pharmaceuticals stock in the last year include Bernice Kuca, Domain Partners Vi, LP, Linda C Hogan, Matthew D Dallas, Raymond Skwierczynski, Thomas P Mathers and Vi Associates LP Dp.
Who bought CoLucid Pharmaceuticals stock? Who is buying CoLucid Pharmaceuticals stock?
CoLucid Pharmaceuticals' stock was purchased by a variety of institutional investors in the last quarter, including Perceptive Advisors LLC, FMR LLC, Marshall Wace LLP, Bogle Investment Management L P DE, J. Goldman & Co LP, Russell Investments Group Ltd., Allianz Asset Management AG and State Street Corp. Company insiders that have bought CoLucid Pharmaceuticals stock in the last two years include A/S Novo, Arthur M Pappas and Thomas P Mathers.
How do I buy CoLucid Pharmaceuticals stock?
Shares of CoLucid Pharmaceuticals can be purchased through any online brokerage account. Popular online brokerages include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.
How much does a share of CoLucid Pharmaceuticals stock cost?
One share of CoLucid Pharmaceuticals stock can currently be purchased for approximately $46.53.